Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
1. Mural is being acquired by XOMA Royalty for up to $2.24 per share. 2. Approval by Mural shareholders and court is needed for the acquisition. 3. Mural's share price has a premium of 13.1% from recent closing prices. 4. Mural will cease operations and wind down after the acquisition closes. 5. The expected closing date is by the end of 2025.